The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys.
about
Neuroprotective effects of (+/-)-kavain in the MPTP mouse model of Parkinson's disease.Neuroprotective effects of compounds with antioxidant and anti-inflammatory properties in a Drosophila model of Parkinson's diseaseThe substantia nigra conveys target-dependent excitatory and inhibitory outputs from the basal ganglia to the thalamus.Remacemide: current status and clinical applications.Riluzole neuroprotection in a Parkinson's disease model involves suppression of reactive astrocytosis but not GLT-1 regulationGlutamate transporter EAAT2: a new target for the treatment of neurodegenerative diseases.Safety and efficacy of perampanel in advanced Parkinson's disease: a randomized, placebo-controlled study.AMPA receptor regulation mechanisms: future target for safer neuroprotective drugs.Identification of a subunit-specific antagonist of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate/kainate receptor channels.Activation of presynaptic kainate receptors suppresses GABAergic synaptic transmission in the rat globus pallidus.Antioxidative therapeutic strategies for Parkinson's disease.A single amino acid determines the subunit-specific spider toxin block of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor channels.Glutamate receptors as therapeutic targets for Parkinson's disease.Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease.Therapeutic potential of targeting glutamate receptors in Parkinson's disease.Advances in non-dopaminergic treatments for Parkinson's diseasePharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.AMPA receptors undergo channel arrest in the anoxic turtle cortex.Mechanism of inhibition of the GluA2 AMPA receptor channel opening by talampanel and its enantiomer: the stereochemistry of the 4-methyl group on the diazepine ring of 2,3-benzodiazepine derivatives.Radiosynthesis and preliminary PET evaluation of (18)F-labeled 2-(1-(3-fluorophenyl)-2-oxo-5-(pyrimidin-2-yl)-1,2-dihydropyridin-3-yl)benzonitrile for imaging AMPA receptors.Metabotropic glutamate receptors for Parkinson's disease therapy.Rearrangement of the dendritic morphology of the neurons from prefrontal cortex and hippocampus after subthalamic lesion in Sprague-Dawley rats.Protection against dopaminergic nigrostriatal cell death by excitatory input ablation.LY293558, an AMPA glutamate receptor antagonist, prevents and reverses levodopa-induced motor alterations in Parkinsonian rats.Metabotropic glutamate receptors 5 blockade reverses spatial memory deficits in a mouse model of Parkinson's disease.Modulation of glutamate-induced intracellular energy failure in neonatal cerebral cortical slices by kynurenic acid, dizocilpine, and NBQX.The non-NMDA glutamate receptor antagonists 6-cyano-7-nitroquinoxaline-2,3-dione and 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline, but not NMDA antagonists, block the intrastriatal neurotoxic effect of MPP+.Systemic administration of NMDA and AMPA receptor antagonists reverses the neurochemical changes induced by nigrostriatal denervation in basal ganglia.Deconstructing behavioral neuropharmacology with cellular specificity.MK-801 prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in primates.Turning behavior induced by injections of glutamate receptor antagonists into the substantia nigra of the rat.Efficacy and safety of perampanel in Parkinson's disease. A systematic review with meta-analysis.Overview: Excitatory Amino Acids;Current Opinion in Therapeutic Patents June 1992
P2860
Q31913332-A750AA84-5538-4FC3-8683-9FF32CE8416DQ33499111-1471F1B7-ED90-4BF7-A0D0-409183E5CCC5Q33707910-8FB11047-D668-47A1-B746-3A2BB2C2A1F9Q34074824-A1E694F3-4379-4B7D-8A95-850BE466BAF6Q34223052-13539DFA-A95D-4CCF-B415-171C97EFDCE9Q34296136-9470427F-EE3C-4271-B6A5-74A08518C045Q34619534-3562CF1D-87BE-4B8B-8FCC-08DD7633F1CBQ35809357-872E7FFB-6E14-46BD-9083-9FA1AC46CA30Q36063415-31C66AFE-1E8F-4803-B3BA-21BDE1D082EEQ36328049-CFA6092D-3D5B-4523-93DF-94814D1A2513Q36349448-C856B14C-86E0-466C-B62E-4A6DD36B0341Q36417671-50BFCC7D-D41B-4476-9B70-3FE14F0308E5Q37585401-0D937072-41F7-4805-AE73-D2B540C80875Q38056852-6D6FA850-D4F4-487A-97CA-DB01FBEE4DB7Q38190016-844ACE2E-5AA8-4D5A-BA2F-BDC64C2CDF36Q38218083-5DEEF47C-AC15-4A38-A36B-5A8550D30E70Q38262418-DE357CC4-E26A-4BF1-81D6-3000886BD0D2Q38459255-1A6F2170-9F1F-4AF0-B173-4308D3B28490Q39931409-88C88BBB-04DA-407D-B555-EEFE07C6E83DQ41634484-6D74C6D5-BD03-4938-905C-EB44F21DABD3Q41818450-40DA991B-8E9F-41AE-8B0B-49D867EAC18FQ42449696-C371EDFB-1CC9-41C9-B2DA-799590B4B8E7Q42487442-E6C33113-256E-4D09-9EEF-058E24AD6B02Q43773506-5D5F1A68-E0E9-41EB-ABAB-F2442BC520F1Q46428813-70D9BFA9-8AE7-49E6-917D-C2D4F61250FBQ46603969-EC57F207-F707-4CE3-A003-4D5AB7BA7A8EQ48148951-FABCB77F-20DB-4A28-B7B1-6F9CB64DE4A7Q48174974-F156AC73-B9D8-43B5-8313-01D68DCDDA12Q48309715-453FF046-1DBC-438C-907E-C309F9356D2EQ48446938-D525F84D-117F-4707-A0EA-86E471E9A935Q48906972-1C3D127D-73DE-48B7-B2E0-26CD7E09C881Q49847028-3AEA01CD-148F-4BDC-8A69-FF0FA1B25784Q58852604-F33A483F-1745-4E97-940F-C8EDB057C5A0
P2860
The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys.
description
1991 nî lūn-bûn
@nan
1991 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
The AMPA receptor antagonist N ...... rats and MPTP-treated monkeys.
@ast
The AMPA receptor antagonist N ...... rats and MPTP-treated monkeys.
@en
The AMPA receptor antagonist N ...... rats and MPTP-treated monkeys.
@nl
type
label
The AMPA receptor antagonist N ...... rats and MPTP-treated monkeys.
@ast
The AMPA receptor antagonist N ...... rats and MPTP-treated monkeys.
@en
The AMPA receptor antagonist N ...... rats and MPTP-treated monkeys.
@nl
prefLabel
The AMPA receptor antagonist N ...... rats and MPTP-treated monkeys.
@ast
The AMPA receptor antagonist N ...... rats and MPTP-treated monkeys.
@en
The AMPA receptor antagonist N ...... rats and MPTP-treated monkeys.
@nl
P2093
P2860
P356
P1433
P1476
The AMPA receptor antagonist N ...... rats and MPTP-treated monkeys.
@en
P2093
Greenamyre JT
Klockgether T
P2860
P304
P356
10.1002/ANA.410300513
P577
1991-11-01T00:00:00Z